AI Insight
The U.S. Food and Drug Administration has approved Moderna's influenza vaccine, as announced by the company on Wednesday. This approval comes approximately six months after the FDA initially rejected the application for review. The vaccine represents Moderna's expansion beyond COVID-19 vaccines into seasonal influenza prevention.
Why it matters
This approval marks a significant development in flu vaccine technology, potentially bringing mRNA-based vaccine platforms to seasonal influenza prevention. It expands patient options for flu protection and validates Moderna's broader vaccine development strategy beyond pandemic response.
Understand the Science
Vaccine manufacturer Moderna said Wednesday the U.S. Food and Drug Administration (FDA) had approved its new influenza vaccine, nearly six months after the regulator briefly rejected an application for review.